CDK12 may be inactivated in patients with metastatic castration-resistant prostate cancer, and may make tumors more responsive to PD-1 inhibitors (CDK12 Changes Telling in Prostate Cancer, 2018). This evidence concerns the gene CDK12 and prostate carcinoma.